Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (19431)	3/23/2006 1:33:17 PM
From: dr.praveen	Read Replies (2) \| Respond to of 52153

Aptamers/Hi Ian, Noxxon licensed Aptamer tech from Archemix which is the leader and holds most of the patents. See the news Archemix and Nuvelo Close Phase I Trial for Thrombin Inhibitor, ARC183 - With "Proof of Concept" Achieved, Companies Actively Pursuing an Optimized Second Generation Molecule at the link below. archemix.com Another one is from Antisoma AS1411 which acquired Aptamera.And you know Macugen from eyetech is another example. AS1411 (formerly AGRO100) is a novel aptamer drug that was added to Antisoma's pipeline through the acquisition of the US cancer company Aptamera in February 2005. It binds to the protein nucleolin, which is normally found inside cells, but which presents on the cell surface in a wide range of cancers. Such binding can induce the death of cancer cells that make nucleolin. AS1411 has been tested in a phase I study of 17 patients and has shown encouraging signs of anti-cancer activity. antisoma.com This link will tell you more about the technology Message 21551234 Regards, Praveen